Latest Advances in Lung Cancer Research

French study finds chemotherapy after lung cancer surgery shows unclear benefits for patients over 75, requiring careful patient selection.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Study shows 70 Gy radiation doses for lung cancer don’t increase pneumonitis risk and may improve survival compared to lower doses.

Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

A new study shows adding immunotherapy to chemotherapy before lung cancer surgery significantly improves five-year survival rates in patients.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).

Study reveals lung cancer itself causes brain structural changes and cognitive impairment in patients before receiving any chemotherapy treatment.

COCOON study shows simple preventive skin care regimen reduces severe skin reactions by 50% in lung cancer patients receiving amivantamab-lazertinib treatment.

Leading lung cancer specialists discuss revolutionary advances in treating EGFR-mutated non-small cell lung cancer, highlighting how new combination therapies like amivantamab plus chemotherapy are doubling progression-free survival and offering hope for patients with challenging complications like leptomeningeal metastases, while emphasizing practical strategies for managing treatment side effects in community practice.